Professor Mark James McKeage

MBChB, MMedSc, PhD, FRACP

Biography

Professor Mark McKeage is a physician-scientist with many years experience as research group leader (Cancer Clinical Pharmacology Research Group), practising medical oncologist, clinical trial investigator, graduate student thesis supervisor, and teacher of pharmacology, oncology and clinical medicine. He has over 100 research articles, over 3500 citations and an H-index of 33. His current research seeks to understand mechanisms and develop treatments for platinum drug neurotoxicity and transport-mediated resistance, and to improve lung cancer healthcare via novel genetic testing strategies and targeted therapies.

Currently Professor in the Department of Pharmacology and Clinical Pharmacology, and Co-director of the Auckland Cancer Society Research Centre, he previously he worked at The Institute of Cancer Research and Royal Marsden Hospital (London UK) and the Prince of Wales Hospital, a teaching hospital of the University of New South Wales. 

Visit the Cancer Clinical Pharmacology Group website

Selected publications and creative works (Research Outputs)

  • Myint, K., Biswas, R., Li, Y., Jong, N., Jamieson, S., Liu, J., ... Lu, J. (2019). Identification of MRP2 as a targetable factor limiting oxaliplatin accumulation and response in gastrointestinal cancer. Scientific reports, 9 (1)10.1038/s41598-019-38667-8
    Other University of Auckland co-authors: Catherine Han, Stephen Jamieson, Christopher Squire
  • Tin Tin, S., McKeage, M. J., Khwaounjoo, P., Thi, A. M., & Elwood, J. M. (2018). Incomplete uptake of EGFR mutation testing and its impact on estimation of mutation prevalence in patients with non-squamous NSCLC: A population-based study in New Zealand. Cancer epidemiology, 57, 24-32. 10.1016/j.canep.2018.09.004
    URL: http://hdl.handle.net/2292/46202
    Other University of Auckland co-authors: Sandar Tin Tin, Mark Elwood
  • Dantzic, D., Noel, P., Merien, F., Liu, D. X., Lu, J., Han, H., ... Li, Y. (2018). The effects of synthetically modified natural compounds on ABC transporters. Pharmaceutics, 10 (3).10.3390/pharmaceutics10030127
  • McKeage, M. J., Kotasek, D., Markman, B., Hidalgo, M., Millward, M. J., Jameson, M. B., ... Xu, L. (2018). Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC. Target Oncol, 13 (1), 89-98. 10.1007/s11523-017-0543-0
    Other University of Auckland co-authors: Michael Jameson
  • Cui, H., Zhang, A. J., McKeage, M. J., Nott, L. M., Geraghty, D., Guven, N., & Liu, J. J. (2017). Copper transporter 1 in human colorectal cancer cell lines: Effects of endogenous and modified expression on oxaliplatin cytotoxicity. Journal of Inorganic Biochemistry, 177, 249-258. 10.1016/j.jinorgbio.2017.04.022
  • McKeage, M., Elwood, M., Tin Tin, S., Khwaounjoo, P., Aye, P., Li, A., ... Kingston, N. (2017). EGFR Mutation Testing of non-squamous NSCLC: Impact and Uptake during Implementation of Testing Guidelines in a Population-Based Registry Cohort from Northern New Zealand. Targeted Oncology, 12 (5), 663-675. 10.1007/s11523-017-0515-4
    URL: http://hdl.handle.net/2292/36730
    Other University of Auckland co-authors: Sandar Tin Tin, Mark Elwood, Don Love, Phyu Aye
  • Shepherd, P., Sheath, K. L., Tin Tin, S., Khwaounjoo, P., Aye, P. S., Li, A., ... Elwood, J. M. (2017). Lung cancer mutation testing: A clinical retesting study of agreement between a real-time PCR and a mass spectrometry test. Oncotarget, 8 (60), 101437-101451. 10.18632/oncotarget.21023
    URL: http://hdl.handle.net/2292/42053
    Other University of Auckland co-authors: Sandar Tin Tin, Don Love, Mark Elwood, Phyu Aye
  • Cho, B. C., Kim, D. W., Bearz, A., Laurie, S. A., McKeage, M., Borra, G., ... Ardizzoni, A. (2017). ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 12 (9), 1357-1367. 10.1016/j.jtho.2017.07.005

Identifiers

Contact details

Primary office location

M&HS BUILDING 504 - Bldg 504
Level 2, Room 236A
85 PARK RD
GRAFTON
AUCKLAND 1023
New Zealand

Web links